Swiss Pharmaceuticals & Biotech Top Stock Picks from Analysts

Cosmo

Market Cap: CHF 1.1b

A life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally.

Kuros Biosciences

Market Cap: CHF 761.2m

Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.

Basilea Pharmaceutica

Market Cap: CHF 661.9m

A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.

Newron Pharmaceuticals

Market Cap: CHF 271.3m

A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.

Santhera Pharmaceuticals Holding

Market Cap: CHF 232.9m

A specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia.

BioVersys

Market Cap: CHF 155.1m

Researches and develops antimicrobial drugs for bacterial infections.

Molecular Partners

Market Cap: CHF 117.4m

A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.

Xlife Sciences

Market Cap: CHF 105.8m

Focuses on the development and commercialization of research projects in the life sciences sector.

MindMaze Therapeutics Holding

Market Cap: CHF 30.5m

Operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally.